Influence of different purification techniques on triamcinolone yield and particle size spectrum

Graefe's Archive for Clinical and Experimental Ophthalmology

Volumn 245, Issue 5, 2007, Pages 689-696

  Szurman, Peter ^a   Kaczmarek, Radoslaw ^a   Jaissle, Gesine B ^a   Grisanti, Salvatore ^a   Lüke, Matthias ^a   Spitzer, Martin S ^a   Heide, Peter Edgar ^a   Bartz Schmidt, Karl U ^a  

^a UNIVERSITY OF TÜBINGEN   (Germany)

Author keywords

Crystalline suspension; Purification; Sedimentation; Triamcinolone

Indexed keywords

CELLULOSE; TRIAMCINOLONE ACETONIDE;

ARTICLE; CENTRIFUGATION; CONTROLLED STUDY; CORRELATION ANALYSIS; CRYSTAL STRUCTURE; DOSE CALCULATION; DRUG PURIFICATION; DRUG RESISTANCE; FILTER DESIGN; INTERMETHOD COMPARISON; MEMBRANE FILTER; PARTICLE RESUSPENSION; PARTICLE SIZE; PREDICTION; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; REPRODUCIBILITY; SEDIMENTATION; SPECTROPHOTOMETRY; STRUCTURE ANALYSIS;

CENTRIFUGATION; CRYSTALLIZATION; FILTRATION; GLUCOCORTICOIDS; PARTICLE SIZE; PHARMACEUTICAL PREPARATIONS; REPRODUCIBILITY OF RESULTS; SUSPENSIONS; TRIAMCINOLONE ACETONIDE;

EID: 34250755079     PISSN: 0721832X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00417-006-0436-x     Document Type: Article

References (22)

1. Antcliff RJ, Spalton DJ, Stanford MR, Graham EM, Ffytche TJ, Marshall J (2001) Intravitreal triamcinolone for uveitic cystoid macular edema: An optical coherence tomography study. Ophthalmology 108:765-772
2. Chandler DB, Rozakis G, de Juan E, Machemer R (1985) The effect of triamcinolone acetonide on a refined experimental model of proliferative vitreoretinopathy. Am J Ophthalmol 99:686-690
3. Danis RP, Ciulla TA, Pratt LM, Anliker W (2000) Intravitreal triamcinolone acetonide in exudative age-related macular degeneration. Retina 20:244-250
4. Garcia-Arumi J, Boixadera A, Giralt J, Martinez-Castillo V, Gomez-Ulla F, Corcostegui B, Garcia-Arumi E (2005) Comparison of different techniques for purification of triamcinolone acetonide suspension for intravitreal use. Br J Ophthalmol 89:1112-1114
5. Hernaez-Ortega MC, Soto-Pedre E (2004) A simple and rapid method for purification of triamcinolone acetonide suspension for intravitreal injection. Ophthalmic Surg Lasers Imaging 35:350-351
6. Hernaez-Ortega MC, Soto-Pedre E (2006) Removal of benzyl alcohol from a commercially available triamcinolone acetonide suspension for intravitreal use. Ophthalmic Surg Lasers Imaging 37:162-164
7. Hida T, Chandler D, Arena JE, Machemer R (1986) Experimental and clinical observations of the intraocular toxicity of commercial corticosteroid preparations. Am J Ophthalmol 101:190-195
8. Hoppe-Tichy T, Bär W, Schmitt S (2005) Zwei intravitreal applizierbare Triamcinolonacetonid-Suspensionen im Vergleich. Krankenhauspharmazie 26:231-232
9. Jaissle GB, Szurman P, Bartz-Schmidt KU (2004) Ocular side effects and complications of intravitreal triamcinolone acetonide Injection. Ophthalmologe 101:121-128
10. Jonas JB, Hayler JK, Panda-Jonas S (2000) Intravitreal injection of crystalline cortisone as adjunctive treatment of proliferative vitreoretinopathy. Br J Ophthalmol 84:1064-1067
11. Jonas JB, Akkoyun I, Budde WM, Kreissig I, Degenring RF (2004) Intravitreal reinjection of triamcinolone for exudative age-related macular degeneration. Arch Ophthalmol 122:218-222
12. Jonas JB (2004) Intraocular availability of triamcinolone acetonide after intravitreal injection. Am J Ophthalmol 137:560-562
13. Martidis A, Duker JS, Greenberg PB, Rogers AH, Puliafito CA, Reichel E, Baumal C (2002) Intravitreal triamcinolone for refractory diabetic macular edema. Ophthalmology 109:920-927
14. Mason JO, Somaiya MD, Singh RJ (2004) Intravitreal concentration and clearance of triamcinolone acetonide in nonvitrectomized human eyes. Retina 24:900-904
15. Morrison VL, Koh HJ, Chen L, Bessho K, Davidson MC (2006) Intravitreal toxicity of the kenalog vehicle (benzyl alcohol) in rabbits. Retina 26:339-344
16. Nishimura A, Kobayashi A, Segawa Y, Sakurai M, Shirao E, Shirao Y, Sugiyama K (2003) Isolating triamcinolone acetonide particles for intravitreal use with a porous membrane filter. Retina 23:777-779
17. Rodriguez-Coleman H, Yuan P, Kim H, Gravlin L, Srivastava S, Csaky KG, Robinson MR (2004) Intravitreal injection of triamcinolone for diffuse macular edema. Arch Ophthalmol 122:1085-1086
18. Ruiz-Moreno JM, Montero JA, Artola A, Barile S (2005) Anterior chamber transit of triamcinolone after intravitreal injection. Arch Ophthalmol 123:129-130
19. Schindler RH, Chandler D, Thresher R, Machemer R (1982) The clearance of intravitreal triamcinolone acetonide. Am J Ophthalmol 93:415-417
20. Szurman P, Kaczmarek R, Spitzer MS, Jaissle GB, Decker P, Grisanti S, Henke-Fahle S, Aisenbrey S, Bartz-Schmidt KU (2006) Differential toxic effect of dissolved triamcinolone and its crystalline deposits on cultured human retinal pigment epithelium (ARPE19) cells. Exp Eye Res 83:584-592, Epub
21. Winkelmeier P, Glauner B, Lindl T (1993) Quantitation of cytotoxicity by cell volume and cell proliferation. Altern Lab Anim 21:269-280
22. Yeung CK, Chan KP, Chiang SWY, Pang CP, Lam DSC (2003) The toxic and stress responses of cultured human retinal pigment epithelium (ARPE19) and human glial cells (SVG) in the presence of triamcinolone. Invest Ophthalmol Vis Sci 44:5293-5300